A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

• Status: Not yet recruiting
• Trial end date: 2027-09-15

Summary

The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma.

The names of the treatment interventions involved in this study are:

• Glofitamab (T-cell bispecific antibody)

• Polatuzumab (antibody-drug conjugate)

• R-CHP (a chemotherapy regimen comprised of Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, and Prednisone)

• Phase: Phase 2

Details

• Lead Sponsor: Philippe Armand, MD, PhD
• Collaborator: Genentech, Inc.
• Treatments: Cyclophosphamide; Doxorubicin; Liposomal doxorubicin; Methylprednisolone; Prednisolone; Prednisone; Rituximab